3B BlackBio Dx schedules one-on-one investor call for September 11

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • 3B BlackBio Dx hosts virtual investor call on September 11, 2026
  • One-on-one meeting scheduled with Capri Global Holdings
  • Company to use Q1-FY27 investor presentation for discussion
  • Disclosure made under Regulation 30 of SEBI LODR Regulations
powered bylight_fuzz_icon
50156633

*this image is generated using AI for illustrative purposes only.

3B BlackBio Dx Limited will host a virtual investor conference call on Friday, September 11, 2026, at 11:00 am. The meeting is scheduled as a one-on-one interaction with Capri Global Holdings in Mumbai.

The company disclosed the schedule pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The interaction will be conducted via an investor conference call mode.

Meeting Details

The company confirmed that only information available in the public domain will be shared during the session. No unpublished price-sensitive information will be discussed.

Parameter Details
Date and Time September 11, 2026 at 11:00 am
Counterparty Capri Global Holdings, Mumbai
Mode Virtual Investor Conference Call
Type One-on-One

Presentation Material

For this meeting, the company will use the Investor Presentation of Q1-FY27. This document was previously intimated to the stock exchange vide Ref.No.P-66/2026-27/27 dated August 13, 2026.

The disclosure was signed by Nikhil Kuber Dubey, Whole Time Director of 3B BlackBio Dx Limited (formerly Kilpest India Limited). The company noted that the date and time are subject to change due to exigencies on the part of the investor or the company.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
-1.76%+8.13%+16.99%0.0%0.0%0.0%

How might the one-on-one engagement with Capri Global Holdings signal potential strategic partnerships or M&A activity for 3B BlackBio Dx?

What specific growth drivers in the Q1-FY27 investor presentation are likely to influence Capri Global Holdings' investment thesis for the company?

Could this targeted investor interaction indicate a broader shift in 3B BlackBio Dx's capital raising strategy or institutional outreach efforts?

3B BlackBio Dx concludes investor meeting with Param Capital on Aug 29

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • 3B BlackBio Dx completed its one-on-one meeting with Param Capital on August 29, 2026
  • The session lasted one hour, running from 1:00 pm to 2:00 pm India Time
  • Discussions centered on Q1-FY27 financial results and the associated investor presentation
  • The company confirmed no unpublished price-sensitive information was shared during the call
powered bylight_fuzz_icon
49207339

*this image is generated using AI for illustrative purposes only.

3B BlackBio Dx Ltd concluded its one-on-one virtual investor meeting with Param Capital on Saturday, August 29, 2026. The session ran from 1:00 pm to 2:00 pm India Time.

The interaction focused on the company’s financial performance for the first quarter of FY27. Management used the Q1-FY27 Investor Presentation, previously intimated to stock exchanges via Ref. No. P-66/2026-27/27 dated August 13, 2026, as the basis for discussion.

Meeting Outcome

The company confirmed that only information available in the public domain was discussed during the call. No unpublished price-sensitive information was shared with the investor. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Parameter Detail
Date August 29, 2026
Time 1:00 pm to 2:00 pm
Counterparty Param Capital, Mumbai
Mode Virtual (Conference Call)
Type One-on-one

Nikhil Kuber Dubey, Whole Time Director, signed the disclosure filed with the Bombay Stock Exchange.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
-1.76%+8.13%+16.99%0.0%0.0%0.0%

How will BlackBio Dx's Q1-FY27 financial performance influence its valuation metrics relative to peers in the diagnostic sector?

What specific growth initiatives or product launches did management highlight as key drivers for FY27 beyond the Q1 results?

Given the one-on-one nature of the meeting, are there indications of increased institutional interest or potential block deals involving Param Capital?

More News on 3B BlackBio DX

1 Year Returns:0.00%